# NCT01449461 (NCT01449461)

> A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

No report yet. It can be ordered.

- Drugs tested: brigatinib
- Indication: ALK-rearranged non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01449461
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Ariad Pharmaceuticals
- Conditions: Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
- Interventions: Brigatinib
- Enrollment: 137
- Primary outcome: Recommended Phase 2 Dose (RP2D) of Brigatinib
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on NCT01449461 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01449461
